#United States #Brooklyn #Cresilon #TRAUMAGEL #hemostatic gel

Cresilon's TRAUMAGEL: A New Standard in Emergency Hemostasis

Cresilon Inc., a pioneering biotechnology firm based in Brooklyn, has announced the nationwide launch of TRAUMAGEL®, a groundbreaking hemostatic gel designed to control bleeding swiftly. This innovative product is set to enhance emergency medical services across the U.S., providing crucial support to EMTs, paramedics, first responders, and trauma centers. TRAUMAGEL joins the ranks of contemporary medical advancements that prioritize rapid intervention in life-threatening scenarios.

What is TRAUMAGEL?

TRAUMAGEL is a plant-based hemostatic solution that works effectively at the site of the wound, promising immediate control of both moderate to severe bleeding. It has received the 510(k) clearance from the U.S. Food and Drug Administration for temporary external use and is supplied in a 30 mL sterile prefilled syringe. This means that it can be deployed without any preparation, saving precious seconds in critical situations where time is of the essence.

The gel's formulation utilizes Cresilon's proprietary hydrogel technology, making it the first hemostatic gel that comes in a syringe and the only flowable hemostatic agent cleared for such use. The technology merges refined plant polymers to create a robust mechanical barrier, ensuring a quick response to hemorrhage.

Positive Field Results

Prior to its nationwide release, Cresilon conducted a strategic rollout in select cities like Boston, New Orleans, Denver, and Columbus. Initial applications in the field showed promising results, with the gel effectively treating various types of injuries, including extremity wounds and lacerations on the head. Frank Tranfaglia, the Trauma Program Manager at a prominent Denver trauma center, noted that TRAUMAGEL performed exceptionally well even in difficult cases, such as stopping bleeding immediately in a patient on blood thinners.

Why is TRAUMAGEL Important?

The ability to stop severe bleeding within moments can drastically change a patient's prognosis in emergencies. CEO and co-founder Joe Landolina emphasized that TRAUMAGEL's swift action could mean the difference between life and death. He remarked, "Our mission is to save lives, and with the launch of TRAUMAGEL, we are making strides toward that goal. This is not just a medical device; it is a revolutionary tool that can redefine trauma care."

Simplicity & Efficiency

Unlike other hemostatic devices and gauze that may require tedious preparation and can be difficult to apply under stress, TRAUMAGEL is designed for ease of use. Its prefilled syringe format eliminates preparation time and allows for rapid application, crucial in emergencies where each second counts. This means that healthcare professionals can focus more on patient care without being hindered by complicated products.

Future of Trauma Care

Cresilon's commitment to innovation in trauma care is evident in its development of TRAUMAGEL. With manufacturing taking place at their state-of-the-art facility in Brooklyn, the company aims to ensure widespread availability of this life-saving technology throughout the U.S.

Healthcare professionals interested in integrating TRAUMAGEL into their emergency protocols can contact Cresilon directly for training sessions. The aim is to facilitate comprehensive product knowledge and on-field practical applications, aligning with Cresilon’s overarching objective of enhancing trauma care.

Conclusion

In a world where trauma care continues to evolve, Cresilon's TRAUMAGEL stands at the forefront, ready to make a substantial impact on how medical emergencies are managed. For more details on Cresilon and TRAUMAGEL's capabilities, you can visit Cresilon's website. The future of emergency bleeding control is here, and TRAUMAGEL is leading the charge to save lives efficiently and effectively.